Early Actions of Anti–Vascular Endothelial Growth Factor/Vascular Endothelial Growth Factor Receptor Drugs on Angiogenic Blood Vessels
作者: Basel SitohySunghee ChangTracey E. SciutoElizabeth MasseMei ShenPeter M. KangShou-Ching JaminetLaura E. BenjaminRupal S. BhattAnn M. DvorakJanice A. NagyHarold F. Dvorak
作者单位: 1The Center for Vascular Biology Research and the Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
2Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts
刊名: The American Journal of Pathology, 2017, Vol.187 (10), pp.2337-2347
来源数据库: Elsevier Journal
DOI: 10.1016/j.ajpath.2017.06.010
原始语种摘要: Tumors induce their heterogeneous vasculature by secreting vascular endothelial growth factor (VEGF)-A. Anti-VEGF/VEGF receptor (VEGFR) drugs treat cancer, but the underlying mechanisms remain unclear. An adenovirus expressing VEGF-A (Ad-VEGF-A 164 ) replicates the tumor vasculature in mice without tumor cells. Mother vessels (MV) are the first angiogenic vessel type to form in tumors and after Ad-VEGF-A 164 . Multiday treatments with a VEGF trap reverted MV back to normal microvessels. We now show that, within hours, a single dose of several anti-VEGF drugs collapsed MV to form glomeruloid microvascular proliferations (GMP), accompanied by only modest endothelial cell death. GMP, common in many human cancers but of uncertain origin, served as an intermediary step in MV reversion to...
全文获取路径: Elsevier  (合作)
分享到:
来源刊物:
影响因子:4.522 (2012)

×
关键词翻译
关键词翻译
  • Actions 操作
  • Growth 生长
  • Blood